El-Kafrawy, SA; Odle, A; Abbas, AT; Hassan, AM; Abdel-Dayem, UA; Qureshi, AK; Wong, LYR; ... Azhar, EI; + view all El-Kafrawy, SA; Odle, A; Abbas, AT; Hassan, AM; Abdel-Dayem, UA; Qureshi, AK; Wong, LYR; Zheng, J; Meyerholz, DK; Perlman, S; Zumla, A; Azhar, EI; - view fewer (2022) SARS-CoV-2-specific immunoglobulin Y antibodies are protective in infected mice. PLoS Pathogens , 18 (9) , Article e1010782. 10.1371/journal.ppat.1010782.

Preview

PDF journal.ppat.1010782.pdf - Published Version Download (2MB) | Preview

Abstract

Safe, passive immunization methods are required against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants. Immunization of chickens with antigen is known to induce specific IgY antibodies concentrated in the egg yolk and has a good safety profile, high yield of IgY per egg, can be topically applied, not requiring parenteral delivery. Our data provide the first evidence of the prophylactic efficacy of Immunoglobulin Y antibodies against SARS-CoV-2 in mice. Lohmann hens were injected with recombinant SARS-CoV-2 RBD protein; IgY-Abs were extracted from the eggs and characterized using SDS-PAGE. Antiviral activity was evaluated using plaque reduction neutralization tests. In additional experiments, IgY-RBD efficacy was examined in mice sensitized to SARS-CoV-2 infection by transduction with Ad5-hACE2 (mild disease) or by using mouse-adapted virus (severe disease). In both cases, prophylactic intranasal administration of IgY-Abs reduced SARS-CoV-2 replication, and reduced morbidity, inflammatory cell infiltration, hemorrhage, and edema in the lungs and increased survival compared to control groups that received non-specific IgY-Abs. These results indicate that further evaluation of IgY-RBD antibodies in humans is warranted.

Download activity - last month

Export as JSONXMLCSV

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as CSVXMLJSON

Archive Staff Only

View Item